bluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Recommendation of “Hold” by Brokerages

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have earned a consensus rating of “Hold” from the twelve research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $5.87.

A number of analysts have weighed in on the company. Bank of America lowered their price target on bluebird bio from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, December 21st. Royal Bank of Canada reiterated a “sector perform” rating and set a $6.00 target price on shares of bluebird bio in a research report on Wednesday. Morgan Stanley raised shares of bluebird bio from an “underweight” rating to an “equal weight” rating and upped their price objective for the stock from $3.00 to $7.00 in a research note on Friday, December 8th. Wedbush reduced their target price on bluebird bio from $1.72 to $1.68 and set a “neutral” rating on the stock in a report on Tuesday, March 19th. Finally, William Blair reaffirmed a “market perform” rating on shares of bluebird bio in a report on Tuesday, January 9th.

Institutional Investors Weigh In On bluebird bio

Several hedge funds and other institutional investors have recently made changes to their positions in the company. US Bancorp DE boosted its holdings in bluebird bio by 885.7% in the second quarter. US Bancorp DE now owns 7,511 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 6,749 shares during the last quarter. Raymond James & Associates bought a new position in shares of bluebird bio in the 1st quarter valued at about $50,000. Stifel Financial Corp acquired a new stake in shares of bluebird bio during the 3rd quarter worth approximately $32,000. Penserra Capital Management LLC bought a new stake in shares of bluebird bio during the first quarter worth approximately $53,000. Finally, Aigen Investment Management LP acquired a new position in bluebird bio in the third quarter valued at approximately $34,000. 87.43% of the stock is owned by institutional investors and hedge funds.

bluebird bio Trading Down 6.2 %

BLUE stock opened at $1.28 on Friday. bluebird bio has a 1-year low of $0.88 and a 1-year high of $5.53. The business’s 50 day moving average is $1.24 and its 200-day moving average is $2.27. The firm has a market cap of $139.96 million, a P/E ratio of -1.73 and a beta of 0.75.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.